Today, elevations in the total and phosphorylated tau concentrations in the cerebrospinal fluid (CSF), along with low Aβ42 levels, are central to the National Institute on Ageing and Alzheimer’s Association [6] and International Working Group [7] research criteria for an AD diagnosis. This evidence concerns the gene MAPT and Alzheimer disease.